Ann: IHL-42X positive phase 2 clinical trial results, page-297

While I have not got an expert scientific background, I’d say yes they will ‘tinker’.

It is worth researching how the endocannabinoid system works in our body. And each of us will be at different levels. I’ve alluded to me having Parkinson’s before (age 45 now) and have been tinkering with my own genetic dosage over the last 3/4 years. My sleep patterns, while assuming they are not at sleep apnea levels, are erratic.

I find that I check my dosage reasonably frequently (I’d guess every 3/4 weeks) if my sleep patterns change or my body function alters.

To me, I’d suggest it would be likely that they can tweak dosage for individual punters as the research matures.

This outcome in the trial is something special for those of us using a cannabinoid. To see a few people in the trial be all but cured is insanely promising. The market will eventually get it right!! Shame that the price has dipped so much on such a brilliant update.